Is Sellas Life Sciences Group Inc (SLS) overvalued? · $1.62B cap
Sellas Life Sciences Group Inc (SLS) is a biotechnology company listed on US.
This page asks whether Sellas Life Sciences Group Inc (SLS) looks expensive on cached numbers — not a short thesis.
Latest reported SLS revenue for 2026-06-30 was $0. Net income was -$9.6M. SLS currently screens at market cap $1.62B.
SLS currently screens at market cap $1.62B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SLS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SLS stock page for the full model, not this heading.
Not investment advice.